Targets › BMX
1 program from 1 company in 11 trials: 6 Phase 3, 5 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Non-receptor tyrosine kinase that plays central but diverse modulatory roles in various signaling processes involved in the regulation of actin reorganization, cell migration, cell proliferation and survival, cell adhesion, and apoptosis. Participates in signal transduction stimulated by growth factor receptors, cytokine receptors, G protein-coupled receptors, antigen receptors and integrins. (UniProt, P51813)
Open in Phaseline: the race on BMX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor | JAK3, ITK, BMX, TEC, TXK | Phase 3 | Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata … | Dec 2026 |
Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Stable Nonsegmental Vitiligo (1) Hidradenitis Suppurativa (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.